Bryden Wood backs industry initiative to tackle climate emergency
Many activities, processes and sites develop organically over time, meaning that the big picture can become confused or even lost altogether.
Standardised solutions mean that detail is available early and can be pre-approved.The variation of the design and interfaces are standardised and controlled: only the differences need to be reviewed.
Rich data representation can provide regulatory reviewers with relevant information in the appropriate format at each stage of the process.Data-rich models can generate automatic reports to demonstrate design compliance.. Simplified systems and processes enable simplified interactions.The Platform Engineering (P-DfMA) Solution described above and the simplification of processes resulting from this design, enable much simpler and standardised interactions between customers and producers and between the various producers that make up the supply chain to deliver these buildings.
This allows us to achieve the scale and speed of refurbishments that are required..Significant amounts of the design are simpler and can be done much more quickly by a wide range of designers.
The components that make up the built solution can be mass produced by existing manufacturing supply chains.
Significant parts of the assembly process can be done by non-nuclear construction supply chain, much more quickly, and decoupled from the nuclear parts of the building.The building blocks are in place and the time has come to make the change.
It’s up to us to build our sustainable future.. To learn more about our Design to Value approach to design and construction, sign up for our monthly newsletter here:.http://bit.ly/BWNewsUpdatesDeveloping our Design to Value approach as pharmaceutical plant design consultants.
In 2012, Bryden Wood and GlaxoSmithKline started working together to try and come up with a different approach to pharmaceutical capital projects.We started from the premise that while a great deal of effort was expended by a lot of expert people within both pharmaceutical and engineering companies, and despite the significant sums being spent, capital projects often failed to meet business requirements.